🔗 Share this article

Given that the United States proceeds with sweeping changes to its vaccine guidelines, a particular individual has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about coronavirus shots during the global health crisis and has zeroed in on alleged deaths following COVID-19 immunization in her short tenure at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Immunization Program

Public health authorities planned to reveal radical revisions to the childhood immunization program recently, bringing the US with the Danish national calendar, it is understood – a significant shift that would place the US out of alignment with much of the world with no evidence for benefit. The announcement has been postponed until the next year.

Rather than the top vaccines chief, Høeg is scheduled to address the audience at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth appointee to run the division this calendar year.

A New Direction at the Agency

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a greater focus upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for ending specific pediatric vaccine recommendations in the US in order to be more like the Danish model, a society with comprehensive healthcare and a population approximately the population of the state of Wisconsin.

To date statements, she has kept her attention on immunizations – usually the domain of Prasad, director of the FDA’s vaccine center – rather than medication approval.

Questions Over Qualifications

The appointee has no obvious background in pharmaceutical research, oversight or leadership, which has been typical for former leaders of the biologics center. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, remarked a neurologist and psychiatrist. “She lacks experience running a scientific study. She lacks experience in running a large organization. She lacks background in drug approvals.”

Previous heads of the center would “grasp legal statutes and the underlying principles of drug development”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that previous people who headed the center have had.”

This division has an vast range of responsibilities at the FDA, she emphasized.

“The public just zeroes in on the new drug program, but the generic program approves thousands of generic drugs. There’s a biosimilars program, over-the-counter program and so forth, and all of those have to be managed,” she noted. “The responsibility you neglect, that is precisely what that I always told people is going to bite you.”

There is also, a significant administrative element to the role, which oversees more than 5,000 employees. “It’s a huge management job, if you do it right,” she said.

Agency Reaction and Controversial Policies

In response to questions about Dr. Høeg's credentials and whether this appointment signifies more teamwork among agency officials on vaccines, a press secretary responded that the “concerns stem from incorrect assumptions”.

“This background aligns with the responsibilities of her role,” the representative explained, noting the period Høeg spent counseling the agency head on “medication safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the agency head's controversial priority voucher program, a disputed rapid medication authorization process that reportedly concerned her predecessors. “By what process are these medications being picked for this expedited pathway? Who makes the calls?” Howard asked. “There’s a lot of lack of transparency going on at the FDA right now.”

Broadly speaking, he stated, “the agency appears to be shifting towards more relaxed oversight of all drugs, except for immunizations.”

Established History on Immunizations

With immunizations, Dr. Høeg has a more established, if concerning, history, critics have noted. She released a study using unverified crowd-sourced reports to assess the frequency of heart inflammation after Covid vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccinations are riskier than they are.

Part of her “policy goals” for the incoming administration encompassed altering rules for recently developed shots and ending “unnecessary” immunizations, she said post-election on a audio program. At the FDA, Høeg has according to sources floated the idea of preventing young men from obtaining COVID-19 vaccinations.

“She’s an all-around ideologue who commences with her preconceived notions and works backwards to retrofit the science in a extremely misleading, fraudulent way,” Howard stated.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|